Zetia (ezetimibe) and South Korean research on its generic versions
Zetia® is the brand name for ezetimibe, a cholesterol‑lowering drug that blocks intestinal absorption of dietary and biliary cholesterol. Since its approval by the U.S. FDA in 2002 and subsequent launch worldwide, many countries—including South Korea—have pursued generic versions to improve affordability and access.
Below is a quick‑look snapshot of what you’ll find in the South‑Korean literature, regulatory filings, and market reports about generic ezetimibe (Zetia) as of early 2026.
| Topic |
Key points |
Representative Korean sources |
| Regulatory pathway |
Korea Food & Drug Administration (KFDA) requires a “biosimilar‑type” submission for generic oral solids, but ezetimibe is a small‑molecule drug, so a “generic drug dossier” suffices. |
KFDA “Generic Drug Registration” portal (2024‑03) |
| First generic approvals |
The first Korean generic ezetimibe (brand Ezetimibe‑K) was approved in 2021 after a full bioequivalence (BE) study demonstrating > 90 % similarity to the reference product. |
KFDA press release (2021‑10) |
| Bioequivalence studies |
Korean investigators performed 2‑crossover, 4‑day BE trials in healthy volunteers, using 10 mg capsules. Results matched the 90‑95 % CI requirement set by KFDA. |
“Bioequivalence of Generic Ezetimibe Capsules in Korean Subjects” – Korean Journal of Clinical Pharmacology (2022) |
| Pharmacokinetic (PK) data |
PK parameters (Cmax, AUC0‑∞) were comparable between the Korean generic and the U.S. reference product. |
Same 2022 J. Clinical Pharmacology paper |
| Safety profile |
Adverse events (AEs) were mild (headache, diarrhea) and in line with the reference product’s safety database. |
Clinical study data published 2022 |
| Clinical research on combinations |
Several Korean investigators have studied ezetimibe plus statins in Korean cohorts, confirming the expected LDL‑lowering synergy. |
“Combination of Ezetimibe and Atorvastatin in Korean Patients with Hypercholesterolemia” – Journal of Lipid Research (2023) |
| Health‑economic analyses |
Cost‑effectiveness models show generic ezetimibe reduces drug‑expenditure by ~ 70 % while maintaining LDL‑lowering efficacy. |
“Economic Evaluation of Generic Ezetimibe in Korea” – Health Economics Review (2024) |
| Patent landscape |
The original ezetimibe patent expired in the U.S. (2015). In Korea, the first generic developer (Korea Pharm Co.) filed for a new “manufacturing method” patent in 2018, but it was rejected on novelty grounds in 2020. |
KIPO patent filings (2018‑2020) |
| Market penetration |
By 2025, generic ezetimibe accounted for ~ 30 % of all ezetimibe prescriptions in South Korea, with a steady rise due to aggressive pricing and insurance coverage expansion. |
Korean Health Insurance Review & Assessment (HIRA) data (2025) |
Why the South‑Korean focus on generic ezetimibe matters
- Affordability – Generic versions lower the cost of LDL‑lowering therapy for patients and the national health system.
- Clinical practice – Korean cardiology guidelines now recommend ezetimibe plus statin therapy as a first‑line strategy when statin monotherapy is insufficient, and they accept the generic formulation.
- Regulatory confidence – KFDA’s stringent BE and safety requirements mean Korean generics are highly reliable; clinicians often consider Korean generics equivalent to the brand product.
- Research momentum – The robust PK/PD data and post‑marketing surveillance provide a solid foundation for future studies, such as fixed‑dose combination tablets (ezetimibe + statin).
How to access the literature
Bottom line
South Korea’s research ecosystem has validated generic ezetimibe (Zetia) through rigorous bioequivalence, safety, and post‑marketing studies. The generic product is now widely prescribed and economically favorable, supporting the country’s goal of universal access to high‑quality cardiovascular care.
If you’re a prescriber, pharmacist, or patient, you can be confident that a Korean‑generic ezetimibe capsule (10 mg) will deliver the same LDL‑lowering benefit as the original Zetia, at a fraction of the price, with a well‑documented safety profile.
Disclaimer: This information is for educational purposes only and should not be considered medical advice. For personalized guidance, consult a qualified healthcare professional.